157 related articles for article (PubMed ID: 23474024)
1. Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®).
Acosta FJ; Ramallo-Fariña Y; Bosch E; Mayans T; Rodríguez CJ; Caravaca A
Schizophr Res; 2013 May; 146(1-3):196-200. PubMed ID: 23474024
[TBL] [Abstract][Full Text] [Related]
2. A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia.
Byerly M; Fisher R; Whatley K; Holland R; Varghese F; Carmody T; Magouirk B; Rush AJ
Psychiatry Res; 2005 Feb; 133(2-3):129-33. PubMed ID: 15740989
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of adherence patterns in schizophrenia using electronic monitoring (MEMS®): A six-month post-discharge prospective study.
Misdrahi D; Tessier A; Husky M; Lange AC; Vrijens B; Llorca PM; Baylé FJ
Schizophr Res; 2018 Mar; 193():114-118. PubMed ID: 28663027
[TBL] [Abstract][Full Text] [Related]
4. Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: a comparison of methods for the measurement of adherence in schizophrenia.
Brain C; Sameby B; Allerby K; Lindström E; Eberhard J; Burns T; Waern M
Eur Neuropsychopharmacol; 2014 Feb; 24(2):215-22. PubMed ID: 24359935
[TBL] [Abstract][Full Text] [Related]
5. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.
Yang J; Ko YH; Paik JW; Lee MS; Han C; Joe SH; Jung IK; Jung HG; Kim SH
Schizophr Res; 2012 Feb; 134(2-3):226-31. PubMed ID: 22133906
[TBL] [Abstract][Full Text] [Related]
6. The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
Byerly MJ; Nakonezny PA; Rush AJ
Schizophr Res; 2008 Mar; 100(1-3):60-9. PubMed ID: 18255269
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of noncompliance in schizophrenia patients using electronic monitoring (MEMS) and its relationship to sociodemographic, clinical and psychopathological variables.
Acosta FJ; Bosch E; Sarmiento G; Juanes N; Caballero-Hidalgo A; Mayans T
Schizophr Res; 2009 Feb; 107(2-3):213-7. PubMed ID: 18849150
[TBL] [Abstract][Full Text] [Related]
8. The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia.
Remington G; Kwon J; Collins A; Laporte D; Mann S; Christensen B
Schizophr Res; 2007 Feb; 90(1-3):229-37. PubMed ID: 17208414
[TBL] [Abstract][Full Text] [Related]
9. Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.
Brain C; Allerby K; Sameby B; Quinlan P; Joas E; Karilampi U; Lindström E; Eberhard J; Burns T; Waern M
Eur Neuropsychopharmacol; 2013 Dec; 23(12):1754-62. PubMed ID: 24091164
[TBL] [Abstract][Full Text] [Related]
10. Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries.
Barbui C; Nosè M; Mazzi MA; Thornicroft G; Schene A; Becker T; Bindman J; Leese M; Helm H; Koeter M; Weinmann S; Tansella M
Int Clin Psychopharmacol; 2006 Nov; 21(6):355-62. PubMed ID: 17012982
[TBL] [Abstract][Full Text] [Related]
11. Should full adherence be a necessary goal in schizophrenia? Full versus non-full adherence to antipsychotic treatment.
Acosta FJ; Ramallo-Fariña Y; Siris SG
Compr Psychiatry; 2014 Jan; 55(1):33-9. PubMed ID: 24183886
[TBL] [Abstract][Full Text] [Related]
12. Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics.
Nakonezny PA; Byerly MJ
Schizophr Res; 2006 Feb; 82(1):107-14. PubMed ID: 16376522
[TBL] [Abstract][Full Text] [Related]
13. Patient compliance in rheumatoid arthritis, polymyalgia rheumatica, and gout.
de Klerk E; van der Heijde D; Landewé R; van der Tempel H; Urquhart J; van der Linden S
J Rheumatol; 2003 Jan; 30(1):44-54. PubMed ID: 12508389
[TBL] [Abstract][Full Text] [Related]
14. [Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia].
Brunot A; Lachaux B; Sontag H; Casadebaig F; Philippe A; Rouillon F; Cléry-Melin P; Hergueta T; Llorca PM; Moreaudefarges T; Guillon P; Lebrun T
Encephale; 2002; 28(2):129-38. PubMed ID: 11972139
[TBL] [Abstract][Full Text] [Related]
15. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia.
Byerly MJ; Thompson A; Carmody T; Bugno R; Erwin T; Kashner M; Rush AJ
Psychiatr Serv; 2007 Jun; 58(6):844-7. PubMed ID: 17535946
[TBL] [Abstract][Full Text] [Related]
16. Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia.
Novick D; Haro JM; Suarez D; Perez V; Dittmann RW; Haddad PM
Psychiatry Res; 2010 Apr; 176(2-3):109-13. PubMed ID: 20185182
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing the choice of new generation antipsychotic medication in the treatment of patients with schizophrenia.
Edlinger M; Hofer A; Rettenbacher MA; Baumgartner S; Widschwendter CG; Kemmler G; Neco NA; Fleischhacker WW
Schizophr Res; 2009 Sep; 113(2-3):246-51. PubMed ID: 19595578
[TBL] [Abstract][Full Text] [Related]
18. Treatment adherence and insight in schizophrenia.
Bitter I; Fehér L; Tényi T; Czobor P
Psychiatr Hung; 2015; 30(1):18-26. PubMed ID: 25867885
[TBL] [Abstract][Full Text] [Related]
19. Schizophrenia: attitudes of patients and professional carers towards the illness and antipsychotic medication.
Rettenbacher MA; Burns T; Kemmler G; Fleischhacker WW
Pharmacopsychiatry; 2004 May; 37(3):103-9. PubMed ID: 15138893
[TBL] [Abstract][Full Text] [Related]
20. Excessive dosing and polypharmacy of antipsychotics caused by pro re nata in agitated patients with schizophrenia.
Fujita J; Nishida A; Sakata M; Noda T; Ito H
Psychiatry Clin Neurosci; 2013 Jul; 67(5):345-51. PubMed ID: 23711166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
